STORM Therapeutics Secures £69M Funding to Accelerate Groundbreaking RNA-Targeted Cancer Therapies

STORM Therapeutics Limited is excited to announce the successful funding round which raised £69,290,000, a pivotal milestone for the company’s aggressive expansion and innovation strategy. As a pioneering biotechnology firm focused on creating novel therapies by targeting RNA modifying enzymes (RME), STORM has established itself as a first mover in a field that explores over 150 reported RNA modifications and approximately 300 enzymes, offering a wealth of untapped therapeutic potential. This significant investment will bolster STORM’s efforts to advance its proprietary pipeline, which includes its flagship candidate, STC-15—a METTL3 inhibitor that has already reached a critical regulatory milestone with an Investigational New Drug (IND) filing and is set to enter Phase I clinical trials in cancer patients. The funds will also support the development of additional small-molecule drug candidates designed to impact a range of diseases including oncology, inflammation, viral infections, and CNS disorders. With its cutting-edge RNA analytics and drug discovery platform, which synergizes in-house expertise at the modern research facilities on the Babraham Research Campus near Cambridge, UK, and strategic collaborations with high-caliber contract research organizations like Evotec, STORM is well-positioned to further its mission. This infusion of capital not only recognizes the company’s innovative approach and robust R&D capabilities but also lays a strong financial foundation for accelerating clinical development, enhancing research activities, and ultimately driving transformative therapies to address critical unmet medical needs across multiple indications.